Our data suggest that the combination of CHK1/CHK2 and WEE1 inhibitors may cause a similar functional impairment, thus providing the rationale for its evaluation in clinical trials for adult ALL patients. The gene discussed is CHEK2; the disease is acute lymphoblastic leukemia.